loading page

Programmed Death-Ligand 1 (PD-L1) Expression in Patients with Primary or Secondary Myelofibrosis
  • +5
  • Francisco Socola,
  • Moayed Ibrahim,
  • Catherine Murphree,
  • Kirtesh Patel,
  • Matthew Mastrodomenico,
  • Nakhle S. Saba,
  • Hana Safah,
  • Janet Schmid
Francisco Socola
AdventHealth Orlando

Corresponding Author:[email protected]

Author Profile
Moayed Ibrahim
Tulane University John W Deming Department of Medicine
Author Profile
Catherine Murphree
Tulane University John W Deming Department of Medicine
Author Profile
Kirtesh Patel
Delta Pathology Group
Author Profile
Matthew Mastrodomenico
Delta Pathology Group
Author Profile
Nakhle S. Saba
Tulane University John W Deming Department of Medicine
Author Profile
Hana Safah
Tulane University John W Deming Department of Medicine
Author Profile
Janet Schmid
Pathology Department at Tulane University
Author Profile

Abstract

It has been described in mice models that Primary Myelofibrosis (PMF) with JAK2-V617F mutation has an increased expression of programmed death-ligand 1 (PD-L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T-lymphocytes. To prove this hypothesis, we quantified PD-L1 expression on 29 bone marrow (BM) biopsies. We created a scoring system to quantify PD-L1 expression in megakaryocytes. We obtained 14 BM with JAK2 positive PMF, 5 JAK2 negative PMF and 10 patients with normal BM biopsies. PD-L1 expression was higher in the JAK2 positive group compared to the control group with a score of 212.6 vs 121.1 (t-value 2.05,p-value 0.025). In addition, the score was higher in the PMF group regardless of JAK2 mutational status when compared to the control group with score of 205.9 vs 121.1(t-value 2.12,p-value 0.021). There was no difference in the PD-L1 score between the JAK2 negative vs the control group 187.2 vs 121.1 (t-value 1.02,p-value 0.162). These findings suggest that PMF patients with a JAK2 mutation have a higher PD-L1 expression in megakaryocytes compared to the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD-L1 expression.
08 Oct 2023Submitted to Cancer Reports
09 Oct 2023Assigned to Editor
09 Oct 2023Submission Checks Completed
09 Oct 2023Review(s) Completed, Editorial Evaluation Pending
13 Oct 2023Reviewer(s) Assigned